Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with...

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2 Trial

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Disclosure

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Outline Slide

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Background

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Primary Objective

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Secondary Objectives

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Design

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Final OPTIMIZE-2 study design

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Demographics, Baseline Characteristics

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

SRE Rate (Primary Endpoint)

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Time-to-First SRE

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Skeletal Morbidity Rate (SMR)

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Safety Summary

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Bone Markers Change from Baseline

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Conclusions

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Back Ups

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Number of Infusions Prior to Study

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting

Renal Adverse Events

Presented By Gabriel Hortobagyi at 2014 ASCO Annual Meeting